BridgeMD
New treatment option for Breast Cancer
Official title Prophylactic Irradiation to the Contralateral Breast for BCAs Patients
ClinicalTrials.gov ID: NCT04960839
What this study is testing
- What it's testing
- Breast cancer is the most common cancer in women worldwide, with high mortality. About 5% to 10% of breast cancers are hereditary.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 70, women only
You may be able to join if
- Female patients, aged 30-70yrs, diagnosed with stage 0-III breast cancer (NCCN-Breast Cancer V2.2019), undergoing the lumpectomy or mastectomy no...
- Patients with a deleterious germline mutation of BRCA 1/2 or PALB2.
- The patients with no contraindictation for irradiation.
- The patients consent for prophylactic irradiation to the contralateral breast.
- The patient may receive any regimen of adjuvant, neoadjuvant chemotherapy, according to the treating physician. The radiation therapy should start at...
You likely can't join if
- Metastatic breast cancer.
- Past history of other cancer besides breast cancer
- Previous irradiation of the breast or chest wall, but not for breast cancer treatment
- Synchronous bilateral breast cancer
- Patients with active connective tissue diseases, pneumonia are excluded due to the potential risk of significant radiotherapeutic toxicity.
See the full eligibility criteria
- Female patients, aged 30-70yrs, diagnosed with stage 0-III breast cancer (NCCN-Breast Cancer V2.2019), undergoing the lumpectomy or mastectomy no more than 1 year. ALND or SLNB should be carried out and the lymph node...
- Patients with a deleterious germline mutation of BRCA 1/2 or PALB2.
- The patients with no contraindictation for irradiation.
- The patients consent for prophylactic irradiation to the contralateral breast.
- The patient may receive any regimen of adjuvant, neoadjuvant chemotherapy, according to the treating physician. The radiation therapy should start at least 2 weeks after the completion of all the chemotherapy cycles.
- The patient may receive endocrine therapy before, during or after study entry.
- The patient may receive target therapy (Trastuzumab) before, during or after study entry.
- The patient must be eligible for MRI examination of the contralateral breast.
- The patient refused prophylactic contralateral mastectomy and oophorectomy.
- Metastatic breast cancer.
- Past history of other cancer besides breast cancer
- Previous irradiation of the breast or chest wall, but not for breast cancer treatment
- Synchronous bilateral breast cancer
- Patients with active connective tissue diseases, pneumonia are excluded due to the potential risk of significant radiotherapeutic toxicity.
The study team makes the final eligibility decision.
Where it's taking place
- Jiangxi, Jiangxi, China
- Shanghai, Shanghai Municipality, China
- Hangzhou, Zhejiang, China
- Singapore, Singapore
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 30 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Jiangxi, Jiangxi, China; Shanghai, Shanghai Municipality, China; Hangzhou, Zhejiang, China; Singapore, Singapore. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.